CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease

Human Immunology

Volumn 71, Issue 11, 2010, Pages 1141-1146

  Liu, Yun ^a,b   Liang, Wei Bo ^a   Gao, Lin Bo ^a   Pan, Xin Min ^a   Chen, Tian Yi ^a   Wang, Yan Yun ^a   Xue, Hui ^a   Zhang, Lu shun ^a   Zhang, Lin ^a  

^a SICHUAN UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

CD86; Chronic obstructive pulmonary disease; CTLA4; Single nucleotide polymorphism

Indexed keywords

CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD86; CHINA; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; T-LYMPHOCYTES;

EID: 77957753104     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.08.007     Document Type: Article

References (57)

1. Cookson W.O. State of the art. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:473-475.
2. Murray C.J., Lopez A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996, 274:740-743.
3. D'Hulst A.I., Vermaelen K.Y., Brusselle G.G., Joos G.F., Pauwels R.A. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005, 26:204-213.
4. Robbins C.S., Franco F., Mouded M., Cernadas M., Shapiro S.D. Cigarette smoke exposure impairs dendritic cell maturation and T cell proliferation in thoracic lymph nodes of mice. J Immunol 2008, 180:6623-6628.
5. Turato G., Zuin R., Saetta M. Pathogenesis and pathology of COPD. Respiration 2001, 68:117-128.
6. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
7. Goronzy J.J., Weyand C.M. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res Ther 2008, 10(Suppl 1):S3.
8. Boussiotis V.A., Freeman G.J., Gribben J.G., Daley J., Gray G., Nadler L.M. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A 1993, 90:11059-11063.
9. Berenson C.S., Wrona C.T., Grove L.J., Maloney J., Garlipp M.A., Wallace P.K., et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 174:31-40.
10. Lofdahl J.M., Wahlstrom J., Skold C.M. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol 2006, 145:428-437.
11. Zhu G., Agusti A., Gulsvik A., Bakke P., Coxson H., Lomas D.A., et al. CTLA4 gene polymorphisms are associated with chronic bronchitis. Eur Respir J 2009, 34:598-604.
12. Harper K., Balzano C., Rouvier E., Mattei M.G., Luciani M.F., Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991, 147:1037-1044.
13. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
14. Tivol E.A., Boyd S.D., McKeon S., Borriello F., Nickerson P., Strom T.B., Sharpe A.H. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997, 158:5091-5094.
15. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to Massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
16. Oosterwegel M.A., Mandelbrot D.A., Boyd S.D., Lorsbach R.B., Jarrett D.Y., Abbas A.K., Sharpe A.H. The role of CTLA-4 in regulating Th2 differentiation. J Immunol 1999, 163:2634-2639.
17. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 2003, 3:383-391.
18. Teutsch S.M., Booth D.R., Bennetts B.H., Heard R.N., Stewart G.J. Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. J Neuroimmunol 2004, 148:218-230.
19. Silverman E.K., Palmer L.J., Mosley J.D., Barth M., Senter J.M., Brown A., et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002, 70:1229-1239.
20. Malhotra A., Peiffer A.P., Ryujin D.T., Elsner T., Kanner R.E., Leppert M.F., Hasstedt S.J. Further evidence for the role of genes on chromosome 2 and chromosome 5 in the inheritance of pulmonary function. Am J Respir Crit Care Med 2003, 168:556-561.
21. Li-Qun G., Wei Z., Shuang-Xia Z., Lin Z., Min-Jia Z., Bin C., et al. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin Endocrinol (Oxf) 2010, 72:248-255.
22. Azizi E., Massoud A., Amirzargar A.A., Mahmoudi M., Soleimanifar N., Rezaei N., et al. Association of CTLA4 Gene polymorphism in Iranian patients with ankylosing spondylitis. J Clin Immunol 2010, 30:268-271.
23. Abdallah A.M., Renzoni E.A., Anevlavis S., Lagan A.L., Munkonge F.M., Fonseca C., et al. A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis. Int J Immunogenet 2006, 33:155-161.
24. Chong K.K., Chiang S.W., Wong G.W., Tam P.O., Ng T.K., Hu Y.J., et al. Association of CTLA-4 and IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in Chinese children. Invest Ophthalmol Vis Sci 2008, 49:2409-2415.
25. Zaletel K., Krhin B., Gaberscek S., Hojker S. Thyroid autoantibody production is influenced by exon 1 and promoter CTLA-4 polymorphisms in patients with Hashimoto's thyroiditis. Int J Immunogenet 2006, 33:87-91.
26. Douroudis K., Laine A.P., Heinonen M., Hermann R., Lipponen K., Veijola R., et al. Association of CTLA4 but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates. Hum Immunol 2009, 70:536-539.
27. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
28. Caramori G., Adcock I. Gene-environment interactions in the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2006, 6:323-328.
29. Steinman L. State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. Proc Am Thorac Soc 2006, 3:484-486.
30. Freeman C.M., Martinez F.J., Han M.K., Ames T.M., Chensue S.W., Todt J.C., et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:1179-1188.
31. Baroja M.L., Luxenberg D., Chau T., Ling V., Strathdee C.A., Carreno B.M., Madrenas J. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J Immunol 2000, 164:49-55.
32. Tomer Y. Unraveling the genetic susceptibility to autoimmune thyroid diseases: CTLA-4 takes the stage. Thyroidology 2001, 11:167-169.
33. Wang X.B., Zhao X., Giscombe R., Lefvert A.K. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002, 3:233-234.
34. Magistrelli G., Jeannin P., Herbault N., Benoit De Coignac A., Gauchat J.F., Bonnefoy J.Y., Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999, 29:3596-3602.
35. Yousefipour G., Erfani N., Momtahan M., Moghaddasi H., Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand 2009, 120:424-429.
36. Chistiakov D.A., Turakulov R.I. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003, 31:21-36.
37. Luszczek W., Kubicka W., Jasek M., Baran E., Cislo M., Nockowski P., et al. CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. Int J Immunogenet 2006, 33:217-224.
38. Almasi S., Erfani N., Mojtahedi Z., Rajaee A., Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun 2006, 7:401-406.
39. Chang J.C., Liu C.A., Chuang H., Ou C.Y., Hsu T.Y., Huang E.Y., Yang K.D. Gender-limited association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphism with cord blood IgE levels. Pediatr Allergy Immunol 2004, 15:506-512.
40. Su T.H., Chang T.Y., Lee Y.J., Chen C.K., Liu H.F., Chu C.C., et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007, 28:1237-1240.
41. Jones A.L., Holliday E.G., Mowry B.J., McLean D.E., McGrath J.J., Pender M.P., Greer J.M. CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain Behav Immun 2009, 23:347-350.
42. Perez-Garcia A., De la Camara R., Roman-Gomez J., Jimenez-Velasco A., Encuentra M., Nieto J.B., et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 2007, 110:461-467.
43. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves disease. J Immunol 2000, 165:6606-6611.
44. Fernandez-Mestre M., Sanchez K., Balbas O., Gendzekhzadze K., Ogando V., Cabrera M., Layrisse Z. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol 2009, 70:532-535.
45. Sun T., Zhou Y., Yang M., Hu Z., Tan W., Han X., et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68:7025-7034.
46. Knight A.K., Serrano D., Tomer Y., Cunningham-Rundles C. CTLA-4 gene exon-1 +49 A/G polymorphism: Lack of association with autoimmune disease in patients with common variable immune deficiency. J Clin Immunol 2007, 27:95-100.
47. Pan X.M., Gao L.B., Liang W.B., Liu Y., Zhu Y., Tang M., et al. CD86 +1057G/A polymorphism and the risk of colorectal cancer. DNA Cell Biol 2010, 29:381-386.
48. Marin L.A., Moya-Quiles M.R., Miras M., Muro M., Minguela A., Bermejo J., et al. Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl Immunol 2005, 15:69-74.
49. van Wijk F., Nierkens S., de Jong W., Wehrens E.J., Boon L., van Kooten P., et al. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. J Immunol 2007, 178:6894-6900.
50. Matsushita M., Tsuchiya N., Oka T., Yamane A., Tokunaga K. New polymorphisms of human CD80 and CD86: lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun 2000, 1:428-434.
51. Turpeinen H., Laine A.P., Nejentsev S., Sjoroos M., Ilonen J., Simell O., et al. CD86 gene polymorphisms: no association with type I diabetes among Finnish subjects. Diabetologia 2002, 45:1041-1042.
52. Delneste Y., Bosotti R., Magistrelli G., Bonnefoy J.Y., Gauchat J.F. Detection of a polymorphism in exon 8 of the human CD86 gene. Immunogenetics 2000, 51:762-763.
53. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
54. Oaks M.K., Hallett K.M., Penwell R.T., Stauber E.C., Warren S.J., Tector A.J. A native soluble form of CTLA-4. Cell Immunol 2000, 201:144-153.
55. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
56. Kouki T., Gardine C.A., Yanagawa T., Degroot L.J. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J Endocrinol Invest 2002, 25:208-213.
57. Ligers A., Teleshova N., Masterman T., Huang W.X., Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001, 2:145-152.